Clinical status and research progress of primary pulmonary mucinous adenocarcinoma / 中国综合临床

Primary pulmonary mucinous adenocarcinoma is a subtype of lung adenocarcinoma, and its epidemiology is similar to other pulmonary adenocarcinoma. Because of its low incidence rate, the survival data of patients with pulmonary mucinous adenocarcinoma are few and often contradictory. KRAS mutations often occur in pulmonary mucinous adenocarcinoma, but EGFR mutations are rare. The expression of PD-L1 in pulmonary mucinous adenocarcinoma is very low. Patients with early pulmonary mucinous adenocarcinoma can benefit from surgery. Lobectomy is still the standard operation at present, but sub lobectomy may also be effective for early pulmonary mucinous adenocarcinoma. Other treatment options include platinum based dual drug chemotherapy, targeted therapy targeting driving genes, and the recent rise of immunotherapy. Future new targets and corresponding treatments should require more research to confirm.

Interpretation of CT images of pulmonary mucinous adenocarcinoma / 中国综合临床

Pulmonary mucinous adenocarcinoma (PMA) is relatively rare. On chest CT, it can be divided into two types: mass type and pneumonia type. Mass type PMA is more common and is difficult to distinguish from other nonsmall cell lung cancer. It is a solid or partial solid nodule or mass, predominantly located in the peripheral field of the lung with lobulation, spiculation, and more prone “vacuole sign”. Pneumonia type PMA has a poor prognosis and is more likely to develop into diffuse, multifocal and multilobular lesions similar to inflammatory manifestations, indicating dissemination along the airway. Typical signs include large areas of low density, low enhancement consolidation, and “dead tree sign”.

Prospect on medical treatment of pulmonary mucinous adenocarcinoma / 中国综合临床

Pulmonary mucinous adenocarcinoma is a subtype of lung adenocarcinoma, among which invasive mucinous adenocarcinoma (IMA) is the most common subtype and is easily misdiagnosed as pneumonia. Its etiology and pathogenesis are unclear and may be related to gene mutations and other factors. Due to its relative rarity and few related studies, guidelines do not provide advices on its treatment. KRAS mutations are common in IMA patients, and Sotorasib may be effective against KRAS G12C mutated IMA. NRG1 fusion is considered to be an important driver of IMA, and afatinib may be effective in treating IMA with NRG1 fusion/rearrangement. PD-L1 expression is very low in IMA patients, while B7-H3 expression is high, so B7-H3 may be a potential immunotherapeutic target.

18F-FDG PET/CT imaging on a case of primary pulmonary mucinous adenocarcinoma / 天津医药

Primary pulmonary mucinous adenocarcinoma (PPMA) is a low incidence subtype of lung adenocarcinoma. Clinical data of a case with PPMA confirmed pathologically were retrospectively analyzed. The case of PPMA was found the primary lesion and lymph node and bone metastases by 18F-FDG PET/CT examination on May 2017 in People's Liberation Army No. 254 Hospital. We discussed the clinical application of PET/CT in the diagnosis, staging and efficacy evaluation of PPMA.

The research progress of primary pulmonary mucinous adenocarcinoma / 实用肿瘤学杂志

Primary pulmonary mucinous adenocarcinoma with a low incidence,a subtype of lung adeno-carcinoma,occurs in adult males because of its no significant clinical specificity,likely to cause misdiagnosis,and patients with adverse prognosis.Thus,we need further to understand this disease and early diagnosis through a va-riety of methods as soon as possible.Surgical treatment is still the preferred mode of this disease.With addition to resecting lesions,it is also further pathological diagnosis,gene testing,tumor staging and prognosis as well as prep-aration for following-up chemotherapy.In recent years,with the continuous development of genetic technology and innovation,the occurrence of this disease has been found to be related to KRAS gene mutation,ALK gene re-arrangement and its related signal pathway.Related gene mutations and signaling pathways can serve as a target for the treatment of this disease,which provides a variety of ideas for the development of new targeted drugs.How-ever,there are still many problems that need further study,including standard chemotherapy for primary pulmona-ry mucinous adenocarcinoma,drug resistance to targeted drugs, and the development of new KRAS inhibitors.This article reviews the definition of primary pulmonary mucinous adenocarcinoma and pathogenesis,diagnosis and some of the latest treatment methods.

The research progress of primary pulmonary mucinous adenocarcinoma / 实用肿瘤学杂志

Primary pulmonary mucinous adenocarcinoma with a low incidence,a subtype of lung adeno-carcinoma,occurs in adult males because of its no significant clinical specificity,likely to cause misdiagnosis,and patients with adverse prognosis.Thus,we need further to understand this disease and early diagnosis through a va-riety of methods as soon as possible.Surgical treatment is still the preferred mode of this disease.With addition to resecting lesions,it is also further pathological diagnosis,gene testing,tumor staging and prognosis as well as prep-aration for following-up chemotherapy.In recent years,with the continuous development of genetic technology and innovation,the occurrence of this disease has been found to be related to KRAS gene mutation,ALK gene re-arrangement and its related signal pathway.Related gene mutations and signaling pathways can serve as a target for the treatment of this disease,which provides a variety of ideas for the development of new targeted drugs.How-ever,there are still many problems that need further study,including standard chemotherapy for primary pulmona-ry mucinous adenocarcinoma,drug resistance to targeted drugs, and the development of new KRAS inhibitors.This article reviews the definition of primary pulmonary mucinous adenocarcinoma and pathogenesis,diagnosis and some of the latest treatment methods.